EdiGene is a world leading genome editing company founded in 2015.
The mission of EdiGene is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery.
We leverage our proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high- throughput genome screening to enable dissection of functional big data in biological contexts.
EdiGene was awarded as one of the ten biotech companies selected by Nature Biotechnology as representing “some of the best (and most richly financed) science that was commercialized from academia”.
Ph.D.Professor in Peking University; Vice Director of Chinese Association of Genome Editing; The Expert of CDE Drug Registration and Assessment Committee. More than 30 papers in NCBI, 8 among which are published by Cell or Nature publishing group，19 are related to genome editing. Impact factor 280+.
EdiGene combined professionals in the fields of genome editing, stem cells modification，product development, regulatory, operation and management. Core members are with degrees from Stanford University, Michigan State University, Wharton School, Lowa State University, Beijing University, Chinese Academy of Science, etc.
Building No.22, Kexueyuan Road, Changping Distriction, Beijing, China
Building 10, No.6, Nanjianger Road, Zhujiang Street, Nansha Distriction, Guangzhou, China
EDIGENE BIOTECHNOLOGY USA INC.
245 FIRST STREET, RIVERVIEW II, 18TH FLOORCAMBRIDGE, MA 02142 USA